tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2024 Dec 19;12(1)
fae718.
doi: 10.1093/ofid/ofae718. eCollection 2025 Jan. Initial Effectiveness of mRNA-1273 Against SARS-CoV-2 Infection and Hospitalization in Young Children
Mary Aglipay[SUP] 1 2 [/SUP], Jonathon L Maguire[SUP] 2 3 4 5 [/SUP], Sarah Swayze[SUP] 6 [/SUP], Ashleigh Tuite[SUP] 1 [/SUP], Muhammad Mamdani[SUP] 2 3 6 7 [/SUP], Charles Keown-Stoneman[SUP] 1 2 [/SUP], Catherine S Birken[SUP] 3 4 8 9 10 [/SUP], Jeffrey C Kwong[SUP] 1 6 11 12 13 14 [/SUP]
Affiliations
Background: Data on mRNA-1273 (Moderna) vaccine effectiveness (VE) in children aged 6 months to 5 years are limited. The objectives of this study were to assess mRNA-1273 vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19)-related hospitalization among children aged 6 months to 5 years during the initial 5 months of the vaccination campaign rollout, as well as to determine whether VE varied by age group (6 months to <2 years vs 2 to 5 years).
Methods: We used a test-negative study with linked health administrative data in Ontario, Canada, to evaluate vaccine effectiveness of mRNA-1273 against symptomatic SARS-CoV-2 infection and COVID-19-related hospitalization from July 28 to December 31, 2022. Participants included symptomatic children aged 6 months to 5 years who were tested by real-time polymerase chain reaction. The primary outcome was symptomatic infection, and the secondary outcome was COVID-19-related hospitalization.
Results: We included 572 test-positive cases and 3467 test-negative controls. Receipt of mRNA-1273 was associated with reduced symptomatic SARS-CoV-2 infection (VE, 90%; 95% CI, 53%-99%) and COVID-19-related hospitalization (VE, 82%; 95% CI, 4%-99%) ≥7 days after the second dose. We were unable to detect heterogeneity in VE across age groups.
Conclusions: Our findings suggest that mRNA-1273 vaccine effectiveness was initially strong against symptomatic SARS-CoV-2 infection and hospitalization in children aged 6 months to 5 years. Further research is needed to understand long-term effectiveness.
Keywords: COVID-19; SARS-CoV-2; children; mRNA-1273; test-negative study; vaccination; vaccine effectiveness.
. 2024 Dec 19;12(1)
fae718.doi: 10.1093/ofid/ofae718. eCollection 2025 Jan. Initial Effectiveness of mRNA-1273 Against SARS-CoV-2 Infection and Hospitalization in Young Children
Mary Aglipay[SUP] 1 2 [/SUP], Jonathon L Maguire[SUP] 2 3 4 5 [/SUP], Sarah Swayze[SUP] 6 [/SUP], Ashleigh Tuite[SUP] 1 [/SUP], Muhammad Mamdani[SUP] 2 3 6 7 [/SUP], Charles Keown-Stoneman[SUP] 1 2 [/SUP], Catherine S Birken[SUP] 3 4 8 9 10 [/SUP], Jeffrey C Kwong[SUP] 1 6 11 12 13 14 [/SUP]
Affiliations
- PMID: 39758749
- PMCID: PMC11697100
- DOI: 10.1093/ofid/ofae718
Background: Data on mRNA-1273 (Moderna) vaccine effectiveness (VE) in children aged 6 months to 5 years are limited. The objectives of this study were to assess mRNA-1273 vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19)-related hospitalization among children aged 6 months to 5 years during the initial 5 months of the vaccination campaign rollout, as well as to determine whether VE varied by age group (6 months to <2 years vs 2 to 5 years).
Methods: We used a test-negative study with linked health administrative data in Ontario, Canada, to evaluate vaccine effectiveness of mRNA-1273 against symptomatic SARS-CoV-2 infection and COVID-19-related hospitalization from July 28 to December 31, 2022. Participants included symptomatic children aged 6 months to 5 years who were tested by real-time polymerase chain reaction. The primary outcome was symptomatic infection, and the secondary outcome was COVID-19-related hospitalization.
Results: We included 572 test-positive cases and 3467 test-negative controls. Receipt of mRNA-1273 was associated with reduced symptomatic SARS-CoV-2 infection (VE, 90%; 95% CI, 53%-99%) and COVID-19-related hospitalization (VE, 82%; 95% CI, 4%-99%) ≥7 days after the second dose. We were unable to detect heterogeneity in VE across age groups.
Conclusions: Our findings suggest that mRNA-1273 vaccine effectiveness was initially strong against symptomatic SARS-CoV-2 infection and hospitalization in children aged 6 months to 5 years. Further research is needed to understand long-term effectiveness.
Keywords: COVID-19; SARS-CoV-2; children; mRNA-1273; test-negative study; vaccination; vaccine effectiveness.